UNCY FY2025 EPS Lifted by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Brookline Capital Management upped their FY2025 EPS estimates for Unicycive Therapeutics in a research note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($0.04) per share for the year, up from their prior estimate of ($0.15). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.04) EPS, FY2026 earnings at $1.52 EPS and FY2026 earnings at $1.52 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13).

Separately, HC Wainwright raised their price objective on Unicycive Therapeutics from $4.00 to $7.50 and gave the stock a “buy” rating in a research report on Tuesday.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ:UNCY opened at $0.52 on Friday. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.49. The company has a market cap of $53.55 million, a P/E ratio of -0.53 and a beta of 2.26. The stock’s 50-day moving average is $0.58 and its 200-day moving average is $0.57.

Institutional Trading of Unicycive Therapeutics

Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC increased its stake in shares of Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after buying an additional 62,881 shares in the last quarter. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics in the 3rd quarter valued at about $29,000. Northern Trust Corp raised its stake in shares of Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock worth $46,000 after acquiring an additional 34,183 shares during the last quarter. Octagon Capital Advisors LP lifted its position in shares of Unicycive Therapeutics by 16.8% during the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock worth $7,942,000 after purchasing an additional 1,441,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock worth $417,000 after purchasing an additional 122,089 shares in the last quarter. 40.42% of the stock is owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.